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Introduction
Germ cell tumors (GCTs), comprising 1% of male cancers 
overall and 5% of male genitourinary malignancies, are 
the most common tumors in young men (1). While 70% 
of patients with advanced GCTs who undergo induction 
chemotherapy with cisplatin-based chemotherapy will be 
cured based on serologic and radiographic response, the 
remaining 30% represent a heterogeneous and challenging 
group of patients (2,3). For those patients with a residual 
mass and normal serum tumor markers (STM), a post-
chemotherapy retroperitoneal lymph node dissection 
(PC-RPLND) is the standard treatment approach. After 
3 cycles of bleomycin, etoposide and cisplatin (BEP), 
the expected histologic breakdown of the PC-RPLND 
specimen is active cancer in 2–9%, teratoma in 64–67% and 
necrosis in 27–31% (4). 
Patients who have persistently elevated STM following 
induction chemotherapy are presumed to have residual 
GCT and salvage chemotherapy is the usual option, 
with PC-RPLND being utilized in select cases. Salvage 
chemotherapy results in STM normalization and further 
tumor regression in 25–70% of cases (5). Following salvage 
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chemotherapy, patients who normalize their STM have 
a higher rate of malignancy in the specimen compared 
with the post-induction specimens (Table 1). As such, a 
post-salvage chemotherapy retroperitoneal lymph node 
dissection (RPLND) is recommended for all patients with 
a residual mass immediately following second-line therapy, 
even if tumor markers completely normalize. Even with this 
approach, the overall long-term results remain poor with 
5-year survival rates of 15–40% in patients who have failed 
induction chemotherapy (6).
The surgical management of patients with rising or 
persistently elevated STM after second line chemotherapy 
has evolved. Several studies have shown benefit as a result of 
desperation and late relapse (LR) surgical resections (7-10). 
Elevated STM after salvage 2nd or 3rd line chemotherapy 
indicates the presence of chemo-refractory disease and 
long-term survival rates with desperation RPLND have 
ranged from 33–75% (11). As such, these patients may 
benefit from surgical resection in selected cases. Based on 
these results, many investigators questioned whether or not 
surgery could be applied earlier in the course of disease, 
potentially obviating the need for salvage chemotherapy 
altogether.
In this review of the literature, we discuss the indications 
for and outcomes related to the surgical management of 
GCTs in the salvage, desperation, and LR settings.
Definitions
When addressing the management of advanced GCT 
through salvage, desperation, or LR surgery, it  is 
worthwhile to define certain disease specific parameters as 
well as the surgical categories.  The diagnosis of relapsed 
testicular GCT occurs when there is either a rise in the 
human chorionic gonadotropin (hCG) or serum alpha 
fetoprotein (AFP) or radiographic progression following a 
complete response (CR) or surgical cure (12). Confirming 
the diagnosis of relapse is crucially important. Early relapse, 
constituting a majority of relapse occurrences, is defined 
as relapses which occur within 2 years of initial treatment 
(13-15). Patients who fail to achieve a CR to induction 
chemotherapy or who relapse within 6 months have a more 
unfavorable prognosis (16). While a rising STM should 
raise concerns for relapsed GCT, there are other widely 
known causes for mild STM elevations in this setting, and 
caution should be taken prior to deciding on aggressive 
intervention. Serum hCG has shown to be elevated in 
mononucleosis, chronic marijuana use, as well as luteinizing 
hormone (LH) elevation, due to the cross-reactivity. 
Additionally, AFP is found to be elevated in benign liver 
disease and can be mildly elevated due to certain hereditary 
conditions. According to Rashdan and Einhorn (2016) an 
AFP of 8–25 ng/mL should never be the only indication 
for salvage therapy unless it represents a clear and sustained 
rise. As a separate word of caution, for patients presenting 
with hCG >50,000 mIU/mL, they may have a rapid decline 
during the first 2 cycles of chemotherapy but may plateau 
and may take several months to normalize. As such, in these 
circumstances, an element of patience is prudent.
There is a diverse classification scheme for RPLNDs 
in the literature. In general, a primary RPLND refers 
to surgery after orchiectomy for clinical stage I (CSI) or 
low volume clinical stage II (CSII) non-seminoma germ 
cell tumour (NSGCT) with normal post-orchiectomy 
STMs. PC-RPLND refers to a surgery after completion 
of chemotherapy. Classically, this includes patients who 
have a residual mass but negative STMs. Residual or 
growing masses after chemotherapy are the result of either 
teratoma or viable GCT. While it is impossible to predict 
the pathology with 100% certainty based on the clinical 
and serologic history, there are certain hints that can help 
predict the histology of resected masses. Growing masses 
that are associated with rising STM typically indicate 
relapsed or persistent GCT while radiographic progression 
without a corresponding rise in STM should raise suspicion 
for growing teratoma. In the absence of radiographic 
progression in the setting of rising markers, sanctuary sites 
must be considered to include the brain and contralateral 
testis, and appropriate investigation of these sites should be 
undertaken.
Under this “PC-RPLND” heading falls the terms salvage 
and desperation RPLND. While used interchangeably at 
some institutions, at Indiana University we define salvage 
RPLND as an operation performed in the setting of an 
enlarged or growing mass following salvage chemotherapy. 
Patients who normalize their tumor marks following salvage 
chemotherapy and have residual radiographic disease are 
recommended to undergo a salvage RPLND. Justification 
for this management strategy was originally supported 
by Fox et al., who showed that 55% of salvage RPLND 
specimens harbored active cancer (17). In the era of taxane-
based salvage chemotherapy, this rate decreased. The group 
from Memorial Sloan Kettering Cancer Center showed that 
14% of their patients who received taxane based salvage 
chemotherapy harbored active cancer compared to 42% 
who received other salvage therapies (18). In spite of the 
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improved rates of active cancer in the specimens, RPLND 
is still uniformly recommended as the rates of active cancer 
remain unacceptably high.
The term desperation RPLND, as described by 
Donohue, refers to a PC-RPLND (either induction or 
salvage chemotherapy) performed in the setting of elevated 
or rising STM (3). Patients who experience progressive 
disease either during or within 4 weeks after completion of 
cisplatin-based chemotherapy are deemed to have platinum 
refractory GCT. Historically, patients who relapsed after 
previously receiving first-line chemotherapy were not 
considered surgical candidates and were given additional 
chemotherapy. However, a surgical cure is possible even 
in the setting of elevated markers after both induction 
and salvage chemotherapy so long as appropriate patient 
selection is undertaken.
LR is defined as the experience of relapse >2 years after 
initial chemotherapy. While it does occur in 1–3% of 
patients, it is more frequent in those patients who present 
with disseminated disease. A pooled analysis of 5,900 
patients revealed LR in 119/3,700 (3.2%) of NSGCT and 
31/2,200 (1.4%) of seminoma patients (19). Most commonly 
occurring within 10 years of diagnosis, the retroperitoneum 
is the most common site of relapse. Because a significant 
fraction of LR occurs in the RP only, with or without 
elevated AFP, and somatic malignant transformation is 
common, LR should be managed surgically if achievable. 
This is often referred to as resection of LR and is defined 
as a PC-RPLND performed for RP recurrence 24 months 
or later after CR to primary therapy (which may or may not 
have included RPLND).
 
Indications for salvage, desperation and LR 
RPLND
 
Assuming normal iza t ion  of  STM’s  a f ter  sa lvage 
chemotherapy, thorough surgical resection of residual 
disease with curative intent should be considered given 
the possibility of residual teratoma or viable GCT (18). 
Up to 50% of patients undergoing salvage resection have 
viable GCT in the resected specimen. When multiple 
metastatic sites are present, all residual disease should be 
resected as there exists histologic discordance between 
sites in 30% of cases (20). That being said, necrosis found 
in the RPLND specimen correlates to necrosis found in 
lung lesions 90% of the time. Some have thus advocated 
for expectant management of lung lesions if the findings 
of the RPLND indicate necrosis to minimize the surgical 
burden and morbidity (21). PC-RPLND following 
salvage chemotherapy may, in certain cases, obviate the 
need for further chemotherapy. Donohue et al. evaluated 
91 patients who underwent PC-RPLND at Indiana 
University following salvage chemotherapy. Fifty-three 
patients were deemed a complete resection, of whom 25 
underwent repeat salvage chemo and 28 did not. Overall, 
12 patients in each group died of disease and there was no 
difference in survival between the two groups (22). As such, 
in the setting of a presumed complete resection, adjuvant 
salvage chemotherapy is currently not recommended. 
While there is a higher likelihood of complications and 
incomplete resection in the salvage setting, this should not 
deter experienced surgeons from proceeding with surgical 
extirpation and reconstruction when indicated. These cases 
more frequently involve concomitant procedures such 
as vascular resection, bowel resection and the removal of 
associated visceral, pulmonary and mediastinal disease.
Patients who have persistently elevated or rising STM 
with surgically resectable disease after chemotherapy should 
be considered for desperation RPLND. Although the 
STM are elevated at the time of surgery, 50% of patients 
have necrosis or teratoma in the final specimen. Chemo-
refractory patients who have resectable disease may achieve 
cure through surgery. In fact, at Indiana University, surgery 
is the preferred approach for patients with initial localized 
disease and who experienced relapse in the same location. 
Murphy et al. (1993) evaluated 48 chemo-refractory patients 
who underwent desperation surgery between 1977–1990 
at Indiana University. In this report, 38/48 patients (79%) 
were rendered grossly free of disease at the time of surgery 
and 29/48 (60%) achieved a serologic remission; 10/48 
(21%) remained continuously free of disease without the 
need for additional treatment at a median of 46 months 
follow-up. Of the 19 patients who relapsed following 
serologic remission, 6 were ultimately without evidence 
of disease with further therapy, 4 of which had additional 
surgery and 2 had high dose chemotherapy (HDCT) with 
autologous bone marrow transplant (BMT) (23). Therefore, 
when systemic options either fail or are not available due 
to patient factors, desperation surgery may be curative in 
selected patients with presumably resectable, low volume 
disease (24).
LR should be managed utilizing a multimodal treatment 
strategy including surgery when complete resection is 
achievable. Salvage chemotherapy is rarely curative and CRs 
are often only achieved with the use of a combined approach 
with surgical resection. Some studies have shown that 
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combining salvage chemotherapy with surgery improves 
the cure rates (25-28). However, at Indiana University 
we advocate for upfront surgery with no chemotherapy 
if the LR appears completely resectable. Even when a 
complete clinical response is achieved after chemotherapy, 
investigators from Memorial Sloan Kettering Cancer 
Center still advocate for consolidative surgery as either 
teratoma or active cancer is still identified frequently (18).
 
Pathologic findings at and outcomes following 
salvage, desperation and LR RPLND
Salvage
At the present time, there is still an absence of completed 
prospective randomized trials comparing outcomes between 
conventional dose salvage chemotherapy and HDCT with 
autologous stem cell transplant. While many Urologists 
and Oncologists eagerly await the phase III “TIGER” trial 
comparing conventional-dose chemotherapy (CDCT) and 
HDCT in the initial salvage setting, the management of the 
patients after salvage chemotherapy is unlikely to change.
Patients  undergoing PC-RPLND after salvage 
chemotherapy demonstrated higher rates of persistent viable 
malignancy and worsened survival outcomes compared with 
patients who received first-line chemotherapy only (see 
Table 1, obtained from Campbell-Walsh Urology, 35, 815-
837.e4, Table 35-6). While overall (OS) and cancer specific 
(CSS) survival ranged from 60% to 75% in this group, Fox 
et al. found that patients having received only induction 
chemotherapy had a CSS of 58.5% compared to those 
receiving salvage chemotherapy (36.7%) (17,18,29). Regarding 
surgery after HDCT, Rick et al. observed a 59% recurrence 
free survival (RFS) and 65% CSS at a median follow-up of 
7.3 years in a cohort of 57 patients (30). Supporting this 
data, Cary et al. reported a 71% OS at a median follow-up of 
4.2 years in their cohort of 77 patients (31).
Several authors have evaluated predictive factors at 
time of salvage RPLND for the presence of active cancer 
in the resected specimen. Marker trends prior to RPLND 
appear to have prognostic relevance. Rising STM are 
Table 1 Postchemotherapy RPLND in high-risk populations
Study No. patients Teratoma (%) Fibrosis (%) Viable malignancy (%) Follow-up (years) CSS or OS (%)
Salvage
Donohue et al., 1998 166 NR NR NR 9.7 61.4
Eggener et al., 2007 71 21 51 28 5 74
HDCT
Rick et al., 2004 57 16 38 46 7.3 65
Cary et al., 2011 77 33.8 27.3 39 4.2 71
Desperation
Donohue et al., 1998 150 NR NR NR 9.7 66
Ravi et al., 1998 30 26.7 27.6 46.7 4.8 57
Albers et al., 2000 30 11 25 64 11 57
Beck et al., 2005 114 34.2 12.3 53.5 6 53.9
Ong et al., 2008 48 25 17 58 4.3 69
Late relapse
Baniel et al., 1995 81 19 0 81 4.8 56.8
George et al., 2003 83 17 0 78 2.4 74.7
Dieckmann et al., 2005 72 NR NR NR NR 58.3
Sharp et al., 2008 75 19 3 78 4.5 61
Reprinted from Campbell-Walsh Urology, 35/11th edition, Rice KR, Cary KC, Masterson TA, Foster RS, Surgery of Testicular Tumors,  
815-837.e4, Copyright (2016), with permission from Elsevier. RPLND, relapse retroperitoneal lymph node dissection.
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associated with both a lower OS as well as a higher risk for 
finding active cancer (9). The absolute value of the markers 
additionally has been evaluated.
Lakes et al. evaluated 149 men who underwent RPLND 
in the setting of elevated STM. Of them, 64% had elevated 
AFP alone, 25% elevated hCG alone and the remaining 
11% with elevation of both STMs. Forty-three percent 
underwent RPLND after induction chemotherapy while 
54% after salvage chemotherapy, of whom 59% had 
received HDCT. Overall active cancer was seen in 36.9%, 
teratoma in 35.6% and necrosis in 26.8%. In patients who 
had AFP rise only, active cancer was seen in 42%, compared 
to 18.4% in hCG alone. In patients with elevation in both 
hCG and AFP, 50% had active cancer (32). Support for the 
prognostic value of the STM elevation came from 2 other 
studies in this space. Habuchi et al. suggested that high 
hCG levels is a predictor for disease-related death (33), 
while Wood et al. showed that all patients with elevated 
hCG levels relapsed after RPLND while only 30% of 
patients with isolated AFP elevation relapsed (24).
Arguably, the completeness of resection is regarded as 
the most important prognostic factor relating to patient 
outcome. While studies have evaluated the effect on mass 
location (retroperitoneal/mediastinal vs. visceral), ultimately, 
it was the ability to achieve complete resection than proved 
more important. In this regard, the ability to achieve a 
complete resection may be influenced by the residual mass 
location. Habuchi et al. reported complete resection in 
82% of patients with retroperitoneal/mediastinal disease 
vs. only 57% of patients with visceral disease (33). While 
the patients with visceral disease do appear to have worse 
overall outcomes, attempts for resection in selected patients 
should not be avoided.
The normalization of tumor markers also has long-term 
prognostic value in regard to outcome. Ong et al. showed 
that patients with persistently elevated STM after resection 
had a 5-year survival of 8% compared to 93% for those 
patients who normalized their markers (34). In combination 
with the findings of necrosis in the resected specimen, 
elevated STM after surgery is particularly worrisome as 
this clearly indicates residual GCT remaining outside the 
attempted region of resection. 
Desperation
Desperation RPLND can have a significant role in the 
successful management of patients with advanced GCT. 
Data from multiple case series report long-term survival 
rates from 33–75%. (11,34). In 2005, Beck et al. reported 
data from 114 patients who underwent RPLND in the 
desperation setting. Active cancer was identified in 53.5% 
of the resected specimens, while 34% revealed teratoma 
and 12.3% revealed necrosis. The median 5-year OS was 
53.9%. Significantly lower OS rates were seen for patients 
with active cancer in the resected tissue (31%), compared 
to teratoma (77%) or fibrosis (85%). Additionally, 
they showed that marker trends prior to RPLND have 
prognostic relevance. Rising STM are associated with 
both a lower OS as well as a higher risk for finding active 
cancer. In the setting of declining STMs, the 5-year OS 
was 93.3% compared to increasing (22.7%) or stable (60%) 
markers. As such, when selecting appropriate patients 
for desperation RPLND with the highest likelihood 
of oncologic benefit, the authors recommended use of 
the following criteria: declining or stable markers after 
chemotherapy, slowly rising markers after prior CR, and 
resectable disease at <3 sites. Additionally, in patients who 
have exhausted all chemotherapy options, or are unable 
to receive additional chemotherapy, it may be offered as a 
last resort, so long as it is believed the disease is completely 
resectable (7).
In 2008, Ong et al. evaluated 48 patients who underwent 
desperation RPLND and broke the patients down by the 
presence of rising STM vs. stable/downtrending STM. 
Overall 58% of patients had active cancer, 25% had 
teratoma and 17% had necrosis. The 5-year OS was 69%. 
Favorable prognostic factors in their study were elevation 
of AFP alone, complete resection, histologic finding of 
differentiated teratoma and a normalization of STM after 
RPLND. In fact, the normalization of STM was the only 
prognostic factor that remained robust on multivariable 
analysis (34).
Cary et al. evaluated 92 patients who had a residual mass 
after HDCT, describing their histologic findings and the 
impact on OS. Overall, 76% received HDCT as 1st line 
salvage while 23% received HDCT as 2nd line or 3rd line, 
with 24% of patients being platinum refractory. Forty-two 
percent of the 92 patients underwent PC-RPLND in the 
desperation setting. Overall, the histologic breakdown was 
38% active cancer, 34% teratoma and 26% necrosis. In 
the subset of patients in the non-desperation setting, the 
histologic breakdown was 20% active cancer, 41% teratoma 
and 39% necrosis. Overall, more active cancer was found in 
patients who received HDCT as ≥2nd line (60%), compared 
to patients who received HDCT as 1st line salvage (33%). 
The 5-year OS of the entire cohort was 70%. The most 
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significant predictor of death was PC-RPLND performed 
in the desperation setting (31).
The approach to patients with combined retroperitoneal 
and mediastinal disease following induction chemotherapy 
is not standardized. While some advocate for staged 
procedures based on the extent of extra-retroperitoneal 
disease based on data from Memorial Sloan-Kettering 
Cancer Center (MSKCC) and widely accepted at high 
volume centers, combination RPLND and mediastinal 
surgery is safe and effective (35). Fadel et al. reported a 
series of 18 patients who underwent a single stage combined 
retroperitoneal and posterior mediastinal resection. Of 
these 18 patients, 4 were in the setting of elevated tumor 
markers. The 5-year OS rate was 92% with a 5-year 
disease-free survival rate of 87%. Of the 4 patients with 
elevated STM, 1 was unable to be completely resected, 
underwent adjuvant chemotherapy and ultimately died of 
disease. Another patient relapsed to the liver but was able to 
be further salvaged with chemotherapy and remained NED. 
The other two had complete serologic responses to surgery 
and remained NED at last follow-up (36). 
Outcomes reported in several retrospective desperation 
series are listed in Table 1 (8,29,37).
 
LR
Among patients presenting with LR, 80% contain viable 
GCT, with yolk sac tumor being the predominant tumor 
subtype (25). When multiple sites of disease are present, 
all residual disease should be resected when possible as 
histologic discordance between sites exists. The appropriate 
management of LR patients should be individualized, as 
there exists a wide variety of presentations. In general, 
marker-negative relapse is consistent with teratoma and 
should be surgically resected. Typically, a cure can be 
achieved with complete resection. If, however, the patient 
presents with marker-positive relapse, this typically indicates 
viable GCT. These cases have traditionally been managed 
using either a surgery-first strategy or chemotherapy 
followed by surgery. Supporting the critical utility of 
surgery in the LR setting, Baniel et al. evaluated 81 patients 
treated for LR at Indiana University. A majority of the 
patients (47/81) presented >5 years after curative treatment 
of the initial disease. Eighty point four percent of patients 
were treated with chemotherapy for the LR and only 26% 
had a CR, with only 3% remaining NED without surgery. 
Nineteen patients had complete surgical resection of active 
cancer or teratoma as part of a multimodal treatment 
strategy and all remained disease free (28). Based on these 
results, the investigators suggested that LR patients have 
a very underwhelming response rate to chemotherapy and 
surgery was the preferred approach. 
The patients receiving chemotherapy upfront usually 
receive this in order to decrease the burden of disease and 
make surgery more feasible. Ronnen et al. evaluated 29 
patients who received salvage chemotherapy in this setting. 
Their population consisted of patients not considered 
surgical candidates because of extensive disease or disease 
in multiple sites. Treatment with paclitaxel, ifosfamide and 
cisplatin (TIP) followed by surgical resection resulted in CR 
in 7/14 (50%) while no other salvage regimen resulted in a 
favorable clinical response, except for one partial response 
to combine paclitaxel plus ifosfamide followed by high-dose 
carboplatin plus etoposide (TI-CE) with stem cell rescue. 
The median survival of the 29 patients was 23.9 months 
with a median follow-up of 50.6 months (38). 
Conclusions
Overall, the management of patients who are not cured by 
induction chemotherapy alone presents a challenge to even 
the most meticulous surgeon. Many authors have advocated 
for the consolidation of surgical care of patients requiring 
salvage or desperation surgery to centers with significant 
experience and the availability of an experienced multi-
disciplinary surgical team to include hepatobiliary, thoracic 
and vascular surgeons. While aggressive surgical resection 
can offer curative treatment in patients in the salvage, 
desperation and LR setting, the single most important 
decision is who to operate on. These surgeries are often 
challenging; however, they can offer long-term survival in 
a significant percentage of these patients when complete 
resection can be achieved and thus the benefit is worth the 
endeavor.
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